• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus

by January 16, 2025
written by January 16, 2025

By Patrick Wingrove

(Reuters) – Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE:NVO), hopes to double the size of its recently acquired contract drugmaker Catalent (NYSE:CTLT) over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.

Novo Holdings last month closed a $16.5 billion deal to buy U.S.-based Catalent. The firm then sold three of Catalent’s plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of its popular weight-loss drug Wegovy.

Jonathan Levy, the Novo Holdings partner who led the deal, in an interview this week said his firm did not want to overcommit to a revenue target before it had a chance to set out a corporate strategy with Catalent’s management.

“But doubling the size of your business over five years is always a nice barometer to work on, and I think we could do something more here from an enterprise value perspective,” Levy told Reuters at the JPMorgan health conference in San Francisco.

Catalent, which had sales of $4.38 billion in 2024, will hold its next board meeting in February, according to Levy.

Levy said he expects more drugmakers that currently rely on manufacturers in China and India to look for western service providers with Trump set to return to the White House on Monday, given his America first focus.

Catalent and Thermo Fisher Scientific (NYSE:TMO) unit Patheon — two of the largest contract drug manufacturers based in the U.S. — could be beneficiaries of such moves.

In addition to his outspoken preference for U.S. manufacturing, Trump has said he will hit China with new tariffs on the first day of his presidency, but Levy did not discuss how that might affect pharmaceuticals.

Levy said Novo Holdings has a venture vehicle with more than 90 biopharmaceutical assets that will be “a tremendous pipeline” for Catalent.

He also said he was closely watching lawmaker efforts to pass a bill that would restrict U.S. business with certain Chinese biotechnology companies, including contract drug manufacturer WuXi AppTec.

“Companies like WuXi, for example, they (will) struggle as a result of it,” Levy said, “and companies like Catalent will benefit.”

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Randstad gets BofA double upgrade
next post
PVH Corp shares tumble on China investigation concerns

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • UK markets are in the eye of the global bond storm
    • Hyundai India drops 5% on debut after record $3.3 billion IPO

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy